drugset
drugset / Trial / NCT07670312

Evaluation of XYA02 in Patients With Advanced Solid Tumors

NCT07670312 ↗

Phase 1/2 Not yet recruiting 190 enrolled XYone Therapeutics, Inc Novotech (Australia) Pty Limited · collab
Non-randomizedSequentialOpen-labelTreatment

Summary

This study will evaluate the safety, tolerability, and efficacy of XYA02 in participants with advanced solid tumors.

Timeline

Start
2026-07-15
Primary completion
2029-07-15
Completion
2030-07-15

Drugs

EvaluationDrugModalityDoseRoute
Subject XYA02 Unknown — Intravenous

Indications

colorectal cancer gastroesophageal junction adenocarcinoma non-small cell lung carcinoma ovarian cancer pancreatic adenocarcinoma